株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

局所ドラッグデリバリーの世界市場 - 2024年までの予測:半固形剤 (クリーム、軟膏、ゲル、ローション)、液剤、固形剤、経皮製品

Topical Drug Delivery Market by Type (Semisolids (Creams, Ointments, Gels, Lotions), Liquids, Solids, Transdermal Products), Route (Dermal, Ophthalmic, Rectal, Vaginal, Nasal), Facility of Use (Homecare, Hospital, Burn Center) - Global Forecast to 2024

発行 MarketsandMarkets 商品コード 482477
出版日 ページ情報 英文 189 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.53円で換算しております。
Back to Top
局所ドラッグデリバリーの世界市場 - 2024年までの予測:半固形剤 (クリーム、軟膏、ゲル、ローション)、液剤、固形剤、経皮製品 Topical Drug Delivery Market by Type (Semisolids (Creams, Ointments, Gels, Lotions), Liquids, Solids, Transdermal Products), Route (Dermal, Ophthalmic, Rectal, Vaginal, Nasal), Facility of Use (Homecare, Hospital, Burn Center) - Global Forecast to 2024
出版日: 2019年08月09日 ページ情報: 英文 189 Pages
概要

局所ドラッグデリバリー市場は、2019年の932億米ドルから、2024年までに1,232億米ドルまで拡大すると見られています。市場は、2019年~2024年のCAGR (複合年間成長率) で、5.7%の成長が予測されています。

当レポートでは、世界の局所ドラッグデリバリー市場について調査分析し、市場概要、産業動向、セグメント別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 局所ドラッグデリバリー市場概要
  • 北米 - 局所ドラッグデリバリー市場:製品別
  • 欧州 - 局所ドラッグデリバリー市場:使用施設別
  • 局所ドラッグデリバリー市場:地域別スナップショット

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題

第6章 局所ドラッグデリバリーの世界市場:製品別

  • イントロダクション
  • 半固形剤
    • クリーム
    • 軟膏
    • ローション
    • ゲル
    • ペースト
  • 液剤
    • 懸濁剤
    • 溶剤
  • 固形剤
    • 粉剤
    • 坐剤
  • 経皮製品
    • 経皮パッチ
    • 経皮半固形剤

第7章 局所ドラッグデリバリーの世界市場:投与経路別

  • イントロダクション
  • 皮膚
  • 直腸

第8章 局所ドラッグデリバリーの世界市場:使用施設別

  • イントロダクション
  • 在宅医療
  • 病院・クリニック
  • 熱傷治療センター
  • その他

第9章 局所ドラッグデリバリーの世界市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第10章 競合情勢

  • 概要
  • 市場シェア分析
  • 競合シナリオ
  • 競合リーダーシップマッピング

第11章 企業プロファイル

  • GLAXOSMITHKLINE
  • JANSSEN GLOBAL SERVICES (JOHNSON & JOHNSONの子会社)
  • BAUSCH HEALTH COMPANIES
  • MERCK & CO.
  • BAYER AG
  • 久光製薬
  • NESTLE SA
  • NOVARTIS AG
  • GLENMARK PHARMACEUTICALS
  • CIPLA
  • CRESCITA THERAPEUTICS INC.
  • MYLAN N.V.

第12章 付録

図表

LIST OF TABLES

  • TABLE 1: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 2: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 3: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 4: TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 5: TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 6: TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 7: TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 8: TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 9: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 10: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 11: TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 12: TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 13: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 14: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 15: TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 16: TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 17: COMPARISON BETWEEN TRANSDERMAL PATCHES AND TRANSDERMAL SEMI-SOLID FORMULATIONS
  • TABLE 18: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 19: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 20: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 21: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL SEMI-SOLIDS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 22: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 23: DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 24: OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 25: RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 26: VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 27: NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 28: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2024 (USD MILLION)
  • TABLE 29: TOPICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 30: TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 31: TOPICAL DRUG DELIVERY MARKET FOR BURN CENTERS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 32: TOPICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 33: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 34: NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 35: NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 36: NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 37: NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 38: NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 39: NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 40: NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 41: NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2024 (USD MILLION)
  • TABLE 42: PRODUCT APPROVALS & LAUNCHES IN THE US MARKET (2017-2019)
  • TABLE 43: US: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 44: US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 45: US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 46: US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 47: US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 48: US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 49: US: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2024 (USD MILLION)
  • TABLE 50: CANADA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 51: CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 52: CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 53: CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 54: CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 55: CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 56: CANADA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2024 (USD MILLION)
  • TABLE 57: RECENT DEVELOPMENTS IN THE EUROPEAN TOPICAL DRUG DELIVERY MARKET, 2015-2018
  • TABLE 58: EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 59: EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 60: EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 61: EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 62: EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 63: EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 64: EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 65: EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2024 (USD MILLION)
  • TABLE 66: DEVELOPMENTS IN THE FIELD OF TOPICAL DRUG DELIVERY IN GERMANY, 2017-2019
  • TABLE 67: GERMANY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 68: GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 69: GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 70: GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 71: GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 72: GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 73: GERMANY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2024 (USD MILLION)
  • TABLE 74: DEVELOPMENTS IN THE TOPICAL DRUG DELIVERY MARKET IN THE UK, 2016-2019
  • TABLE 75: UK: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 76: UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 77: UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 78: UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 79: UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 80: UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 81: UK: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2024 (USD MILLION)
  • TABLE 82: FRANCE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 83: FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 84: FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 85: FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 86: FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 87: FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 88: FRANCE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2024 (USD MILLION)
  • TABLE 89: ROE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 90: ROE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 91: ROE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 92: ROE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 93: ROE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 94: ROE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 95: ROE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2024 (USD MILLION)
  • TABLE 96: DEVELOPMENTS IN THE TOPICAL DRUG DELIVERY MARKET IN THE ASIA PACIFIC, 2016-2019
  • TABLE 97: ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 98: ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 99: ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 100: ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 101: ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 102: ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 103: ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 104: ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2024 (USD MILLION)
  • TABLE 105: JAPAN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 106: JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 107: JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 108: JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 109: JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 110: JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 111: JAPAN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2024 (USD MILLION)
  • TABLE 112: CHINA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 113: CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 114: CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 115: CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 116: CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 117: CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 118: CHINA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2024 (USD MILLION)
  • TABLE 119: INDIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 120: INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 121: INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 122: INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 123: INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 124: INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 125: INDIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2024 (USD MILLION)
  • TABLE 126: ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 127: ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 128: ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 129: ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 130: ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 131: ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 132: ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2024 (USD MILLION)
  • TABLE 133: ROW: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 134: ROW: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 135: ROW: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 136: ROW: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 137: ROW: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 138: ROW: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 139: ROW: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2024 (USD MILLION)
  • TABLE 140: PRODUCT LAUNCHES
  • TABLE 141: EXPANSIONS
  • TABLE 142: AGREEMENTS AND COLLABORATIONS
  • TABLE 143: ACQUISITIONS

LIST OF FIGURES

  • FIGURE 1: TOPICAL DRUG DELIVERY MARKET SEGMENTATION
  • FIGURE 2: TOPICAL DRUG DELIVERY MARKET: RESEARCH METHODOLOGY
  • FIGURE 3: RESEARCH DESIGN
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 6: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 7: DATA TRIANGULATION METHODOLOGY
  • FIGURE 8: TOPICAL DRUG DELIVERY MARKET SHARE, BY PRODUCT, 2018
  • FIGURE 9: TOPICAL DRUG DELIVERY MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2018
  • FIGURE 10: TOPICAL DRUG DELIVERY MARKET SHARE, BY FACILITY OF USE, 2018
  • FIGURE 11: GEOGRAPHIC SNAPSHOT: TOPICAL DRUG DELIVERY MARKET, 2018
  • FIGURE 12: HIGH PREVALENCE OF SKIN DISEASES AND HIGH INCIDENCE OF BURN INJURIES TO DRIVE THE GROWTH OF THE TOPICAL DRUG DELIVERY MARKET
  • FIGURE 13: SEMI-SOLID FORMULATIONS TO DOMINATE THE NORTH AMERICAN MARKET DURING THE FORECAST PERIOD
  • FIGURE 14: HOME CARE SETTINGS TO DOMINATE THE EUROPEAN MARKET DURING THE FORECAST PERIOD
  • FIGURE 15: US TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 16: TOPICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17: SEMI-SOLID FORMULATIONS SEGMENT TO COMMAND THE LARGEST SHARE OF THE MARKET IN 2019
  • FIGURE 18: DERMAL DRUG DELIVERY TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
  • FIGURE 19: HOME CARE SETTINGS SEGMENT TO COMMAND THE LARGEST SHARE OF THE MARKET IN 2019
  • FIGURE 20: TOPICAL DRUG DELIVERY MARKET, BY REGION, 2019 VS. 2024
  • FIGURE 21: NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
  • FIGURE 22: EUROPE: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
  • FIGURE 23: ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
  • FIGURE 24: REST OF THE WORLD: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
  • FIGURE 25: MARKET SHARE ANALYSIS BY KEY PLAYERS (2018)
  • FIGURE 26: TOPICAL DRUG DELIVERY MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2018
  • FIGURE 27: GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • FIGURE 28: JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • FIGURE 29: BAUSCH HEALTH COMPANIES: COMPANY SNAPSHOT
  • FIGURE 30: MERCK & CO.: COMPANY SNAPSHOT
  • FIGURE 31: BAYER AG.: COMPANY SNAPSHOT
  • FIGURE 32: HISAMITSU PHARMACEUTICAL: COMPANY SNAPSHOT 163  
  • FIGURE 33: NESTLE SA: COMPANY SNAPSHOT
  • FIGURE 34: NOVARTIS AG: COMPANY SNAPSHOT
  • FIGURE 35: GLENMARK PHARMACEUTICALS: COMPANY SNAPSHOT
  • FIGURE 36: CIPLA: COMPANY SNAPSHOT
  • FIGURE 37: CRESCITA THERAPEUTICS: COMPANY SNAPSHOT (2018)
  • FIGURE 38: MYLAN: COMPANY SNAPSHOT (2018)
目次
Product Code: MD 5119

"The topical drug delivery market is projected to grow at a CAGR of 5.7% during the forecast period (2019-2024)."

The topical drug delivery market is projected to reach USD 123.2 billion by 2024 from USD 93.2 billion in 2019, at a CAGR of 5.7%. The growth of the topical drug delivery market is driven mainly by the high prevalence of skin disease, rising incidences of eye diseases, high incidence of burn injuries, and the growing prevalence of diabetes. Additionally, emerging markets such as China and India are expected to offer potential growth opportunities to market players in the coming years. However, preference for alternative modes of drug delivery such as oral, injectables, pulmonary, among others could restrict the growth of this market.

By product, the semi-solid formulations segment is expected to account for the largest share of the topical drug delivery market

Based on product, the topical drug delivery market is segmented into semi-solid formulations (creams, gels, ointments, pastes, and lotions), solid formulations (suppositories and powders), liquid formulations (solutions and suspensions), and transdermal products (transdermal patches and transdermal semi-solids). The semi-solid formulations segment is expected to account the largest market share of the topical drug delivery market in 2019. This is mainly due to their easy application and ability to topically deliver a wide variety of drug molecules compared to other formulations.

By route of administration, dermal drug delivery segment to dominate the topical drug delivery market during the forecast period

The dermal drug delivery segment accounted for the largest share of the market in 2018. This is mainly due to the high prevalence of skin diseases across the globe. For instance, According to the WHO, between 2 and 3 million cases of non-melanoma skin cancer and 132,000 cases of melanoma skin cancer are diagnosed annually across the globe.

By facility of use, homecare settings segment to dominate the topical drug delivery market during the forecast period

The homecare settings segment accounted for the largest share of the market in 2018. This is mainly due to the ease of use of topical products at home, better affordability, and advantages of topical and transdermal patches for patients who require a constant drug level as well as those suffering from chronic diseases at homecare settings.

"North America is expected to witness the highest growth during the forecast period."

North America is expected to account for the largest share of the global topical drug delivery market in 2019, followed by Europe. However, Japan is expected to witness the highest CAGR during the forecast period. This can primarily be attributed to the rising geriatric population, increasing the inflow of generic drugs, a growing number of product approvals and launches, and the increasing focus of local players on the R&D of topical formulations in the country. For instance, in November 2018, Santen Pharmaceutical Co., Ltd. (Japan) and Ube Industries (Japan) launched the topical EYBELIS Ophthalmic Solution 0.002% in Japan. Similarly, in September 2018, Santen Pharmaceutical Co., Ltd. (Japan) signed a development and drug discovery agreement with PeptiDerm Inc. (Japan) for developing topical ophthalmic products. Furthermore, in June 2017, LEO Pharma (Denmark) partnered with Kyowa Hakko Kirin Co., Ltd. (Japan) for the development of a topical gel formulation for the treatment of psoriasis.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-55%, Tier 2-25%, and Tier 3-20%
  • By Designation: C-level-43%, Director-level-32%, and Others-25%
  • By Region: North America-38%, Europe-29%, Asia Pacific-23%, Rest of World-10%

The prominent players in the topical drug delivery market are: Nestle SA (Switzerland), Johnson & Johnson (US), Bausch Health Companies (Canada), Novartis AG (Switzerland), GlaxoSmithKline (UK), Bayer AG (Germany), Hisamitsu Pharmaceutical (Japan), Mylan (US) Glenmark Pharmaceuticals (India), Cipla Ltd (India), Crescita Therapeutics Inc. (Canada), and Merck & Co (US).

Research Coverage:

The report analyzes the topical drug delivery market and aims at estimating the market size and future growth potential of the topical drug delivery market and the different segments such as dermal, ophthalmic, rectal, vaginal, and nasal drug delivery. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the topical drug delivery market.
  • Product & Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launch in the topical drug delivery market.
  • Market Development: Comprehensive information on lucrative emerging regions.
  • Market Diversification: Exhaustive information about new products and services, growing geographies, and recent developments in the global topical drug delivery market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products & services of the leading players in the topical drug delivery market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.2 TOP-DOWN APPROACH
    • 2.2.3 GROWTH FORECAST
  • 2.3 MARKET DATA VALIDATION AND TRIANGULATION
  • 2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW
  • 4.2 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2018
  • 4.3 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2018
  • 4.4 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 High prevalence of skin diseases
      • 5.2.1.2 Rising prevalence of eye diseases
      • 5.2.1.3 High incidence of burn injuries
      • 5.2.1.4 Growing prevalence of diabetes
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Preference for alternative modes of drug delivery
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Delivery of biologics through the transdermal route
      • 5.2.3.2 Self-administration and home care
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Technical barriers related to skin irritation and permeability
      • 5.2.4.2 Drug failures and product recalls

6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 SEMI-SOLID FORMULATIONS
    • 6.2.1 CREAMS
      • 6.2.1.1 Ease of spreadability and washability to drive this market segment
    • 6.2.2 OINTMENTS
      • 6.2.2.1 Ointments are widely used in analgesic indications
    • 6.2.3 LOTIONS
      • 6.2.3.1 Easy administration of lotions to drive their demand among end users
    • 6.2.4 GELS
      • 6.2.4.1 Faster drug release and greater patient acceptability to drive the market for topical gels
    • 6.2.5 PASTES
      • 6.2.5.1 Topical pastes are widely used for the treatment and prevention of skin irritation
  • 6.3 LIQUID FORMULATIONS
    • 6.3.1 SUSPENSIONS
      • 6.3.1.1 Higher rate of bioavailability and controlled onset of action to support the growth of the topical suspensions market
    • 6.3.2 SOLUTIONS
      • 6.3.2.1 Topical solutions comprise soluble chemicals that are dissolved in various solvents
  • 6.4 SOLID FORMULATIONS
    • 6.4.1 POWDERS
      • 6.4.1.1 Powders have a very fine particle size that covers a large surface area per unit weight
    • 6.4.2 SUPPOSITORIES
      • 6.4.2.1 Suppositories require a suitable base that ensures the compatibility and stability of the drug
  • 6.5 TRANSDERMAL PRODUCTS
    • 6.5.1 TRANSDERMAL PATCHES
      • 6.5.1.1 Transdermal patches to account for the largest share of

the transdermal drug delivery market in 2019 60

    • 6.5.2 TRANSDERMAL SEMI-SOLIDS
      • 6.5.2.1 Transdermal semi-solids segment to witness negative growth during the forecast period

7 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION

  • 7.1 INTRODUCTION
  • 7.2 DERMAL DRUG DELIVERY
    • 7.2.1 DERMAL DRUG DELIVERY IS THE LARGEST SEGMENT IN THIS MARKET DUE TO ADVANTAGES SUCH AS EASE OF USE AND INCREASED PATIENT COMPLIANCE
  • 7.3 OPHTHALMIC DRUG DELIVERY
    • 7.3.1 INCREASING USE OF MOBILE DEVICES IS LIKELY TO IMPACT VISION, WHICH IS A KEY FACTOR SUPPORTING MARKET GROWTH
  • 7.4 RECTAL DRUG DELIVERY
    • 7.4.1 POOR ABSORPTION OF DRUGS THROUGH THE RECTAL ROUTE-A KEY DISADVANTAGE ASSOCIATED WITH THIS MARKET SEGMENT
  • 7.5 VAGINAL DRUG DELIVERY
    • 7.5.1 HIGH PERMEABILITY OF VAGINAL TISSUES, THE SCOPE OF SELF-ADMINISTRATION, AND EASE OF MANUFACTURING ARE EXPECTED TO BOOST THE GROWTH OF THE VAGINAL DRUG DELIVERY MARKET SEGMENT
  • 7.6 NASAL DRUG DELIVERY
    • 7.6.1 ABSENCE OF DRUG DEGRADATION, HIGH EFFICACY OF NASALLY ADMINISTERED DRUGS, AND GROWING PREFERENCE FOR SELF-ADMINISTRATION TO DRIVE MARKET GROWTH

8 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE

  • 8.1 INTRODUCTION
  • 8.2 HOME CARE SETTINGS
    • 8.2.1 HOME CARE SETTINGS ACCOUNTED FOR THE LARGEST SHARE IN 2018
  • 8.3 HOSPITALS AND CLINICS
    • 8.3.1 RISING INCIDENCE OF SURGICAL SITE INFECTIONS TO DRIVE THIS SEGMENT
  • 8.4 BURN CENTERS
    • 8.4.1 HIGH INCIDENCE OF BURN INJURIES ACROSS THE GLOBE TO SUPPORT

THE MARKET GROWTH 76

  • 8.5 OTHER FACILITIES

9 TOPICAL DRUG DELIVERY MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    • 9.2.1 US
      • 9.2.1.1 Rising prevalence of skin diseases and the approval and launch of innovative topical formulations-key factors driving market growth
    • 9.2.2 CANADA
      • 9.2.2.1 Rising prevalence of skin diseases and funding for the development of topical drugs to drive market growth
  • 9.3 EUROPE
    • 9.3.1 GERMANY
      • 9.3.1.1 Growing focus of pharmaceutical companies on the development of topical products to drive market growth
    • 9.3.2 UK
      • 9.3.2.1 Rising prevalence of skin diseases & chronic conditions to drive market growth
    • 9.3.3 FRANCE
      • 9.3.3.1 Rising prevalence of skin diseases and development of topical drugs by local players to support market growth
    • 9.3.4 REST OF EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 JAPAN
      • 9.4.1.1 Increasing number of product approvals and growing focus of local players on the R&D of topical formulations to support market growth
    • 9.4.2 CHINA
      • 9.4.2.1 Growing focus of major players in China on the development of topical drugs to drive market growth
    • 9.4.3 INDIA
      • 9.4.3.1 Rising awareness among healthcare providers & patients and increasing focus on noninvasive methods of drug delivery

to drive market growth 132

    • 9.4.4 REST OF ASIA PACIFIC
  • 9.5 REST OF THE WORLD

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 MARKET SHARE ANALYSIS
    • 10.2.1 JOHNSON & JOHNSON
    • 10.2.2 NESTLE SA (GALDERMA)
    • 10.2.3 NOVARTIS
  • 10.3 COMPETITIVE SCENARIO
    • 10.3.1 PRODUCT LAUNCHES
    • 10.3.2 EXPANSIONS
    • 10.3.3 AGREEMENTS AND COLLABORATIONS
    • 10.3.4 ACQUISITIONS
  • 10.4 COMPETITIVE LEADERSHIP MAPPING (OVERALL MARKET) (2018)
    • 10.4.1 VISIONARY LEADERS
    • 10.4.2 INNOVATORS
    • 10.4.3 DYNAMIC DIFFERENTIATORS
    • 10.4.4 EMERGING COMPANIES

11 COMPANY PROFILES

(Business overview, Products offered, Recent developments, MNM view)*

  • 11.1 GLAXOSMITHKLINE
  • 11.2 JANSSEN GLOBAL SERVICES (A SUBSIDIARY OF JOHNSON & JOHNSON)
  • 11.3 BAUSCH HEALTH COMPANIES
  • 11.4 MERCK & CO.
  • 11.5 BAYER AG
  • 11.6 HISAMITSU PHARMACEUTICAL
  • 11.7 NESTLE SA
  • 11.8 NOVARTIS AG
  • 11.9 GLENMARK PHARMACEUTICALS
  • 11.10 CIPLA
  • 11.11 CRESCITA THERAPEUTICS INC.
  • 11.12 MYLAN N.V.

Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 RELATED REPORTS
  • 12.4 AUTHOR DETAILS
Back to Top